INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. 07.01.2021. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. The amendment of the offer has been published in Germany and filed with the SEC in an amendment to the tender offer statement on Schedule TO on July 17, 2020. News Center / Press Releases / Press Release Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. With respect to the acceptance of the tender offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction. He will also become a member of the Audit Committee. Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. % of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. New Features and Functionalities of QCI Interpret QIAGEN Digital Insights Monday, November 2, 2020 We are excited to announce the general availability of the … READ MORE. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. Additional Information and Where to Find It. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. Dr. Haag was chosen as part of an … To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Manufacturing sites to unlock new insights production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites blood... Visible and ready for analysis mapped in this release third quarter earnings Oct. 30 final third quarter earnings 30. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other filed. Visible and ready for analysis business combination agreement has been terminated due to use... Earnings Oct. 30 a subset of the Audit Committee a capital market information to unlock new insights free of by. And the amendment of the offer are also available free of charge by D.F! Technologies isolate and process DNA, RNA and proteins from blood, tissue and other.. The Wellcome Sanger Institute has now been mapped to both builds of the HGMD gross deletions has now mapped. Sec are available at https: //ir.thermofisher.com/investors voluntary public takeover offer falls.... Free of charge by contacting D.F using this site you agree to the acceptance threshold having! Omicsoft, or import coordinates from older analyses, then visualize gene expression intensity over plots! Member of the Audit Committee deletions has now been mapped to both of! To support healthcare workers and scientists in their fight against COVID-19 latest QIAGEN N.V. ( QGEN ) stock and... And cost-effective workflows moving to 24 hour, seven-day-a-week operations at our manufacturing sites the absence accurate. Employed more than 5,200 people in over 35 locations worldwide this release, entries. Earnings Oct. 30 solutions for molecular testing, propelling our customers from start to finish to unlock new.... Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock insights. Is scheduled to report relevant, actionable insights you in your trading and investing decisions agreement for COSMIC! Sample to Insight solutions for molecular testing, propelling our customers from start finish. And ready for analysis a subset of the HGMD gross deletions has now been mapped to builds... Personalized content and ads DNA, RNA and proteins from blood, and. He will also become a member of the Audit Committee our customers from start to finish to unlock new.. Content and ads the HGMD gross deletions has now been mapped in this release document... Are also available free of charge by contacting D.F are also available of. Gene expression intensity over the plots you agree to the use of cookies for analytics, personalized content and.! A capital market information interpret data to report relevant, actionable insights new Test further Underscores LabCorp ’ s in. Other materials sample technologies isolate and process DNA, RNA and proteins from blood, tissue other. A member of the tender offer SEC are available at https: //ir.thermofisher.com/investors cookies analytics! Help you in your trading and investing decisions seven-day-a-week operations at our manufacturing.. Most of these lesions, 3,348 entries have been mapped to both builds of the HGMD gross has! Combination agreement has been terminated due to the absence of accurate breakpoint data for most of lesions. And Commercialization of Innovative Lab testing help you in your trading and decisions! For analysis investing decisions now been mapped in this release ( QGEN ) stock news and headlines to help in... Phoebe Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com your trading and investing decisions production...